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Abstract
Mutations in three genes (PSEN1, PSEN2, and APP) have been identified in patients with early-onset
(<65years) Alzheimer’s disease (AD). We performed a screening for mutations in the coding regions
of presenilins, as well as exons 16 and 17 of the APP gene in a total of 231 patients from the Iberian
peninsular with a clinical diagnosis of early onset AD (mean age at onset of 52.9 years; range 31–
64). We found three novel mutations in PSEN1, one novel mutation in PSEN2, and a novel mutation
in the APP gene. Four previously described mutations in PSEN1 were also found. The same analysis
was carried in 121 elderly healthy controls from the Iberian peninsular, and a set of 130 individuals
*Corresponding author: Jordi Clarimón, PhD. Memory Unit. Alzheimer’s Laboratory. Neurology Department. Hospital de la Santa Creu
i Sant Pau. Sant Antoni Ma Claret 167. Barcelona 08025. Spain. (Phone) +34 93 291 90 50 ext.2185. (Fax) +34 93 291 91 78
jclarimon@santpau.cat.
Disclosure Statement for Authors
The authors have nothing to disclose.
NIH Public Access
Author Manuscript
Neurobiol Aging. Author manuscript; available in PMC 2010 May 1.
Published in final edited form as:
Neurobiol Aging. 2010 May ; 31(5): 725–731. doi:10.1016/j.neurobiolaging.2008.06.012.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
from seven African populations belonging to the Centre d’Etude du Polymorphisme Humain-Human
Genome Diversity Panel (CEPH-HGDP), in order to determine the extent of normal variability in
these genes. Interestingly, in the latter series, we found five new nonsynonymous changes in all three
genes and a presenilin 2 variant (R62H) that has been previously related to AD. In some of these
mutations, the pathologic consequence is uncertain and needs further investigation. To address this
question we propose and use a systematic algorithm to classify the putative pathology of AD
mutations.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia, accounting for more than
50% of all cases in adults. It is a progressive neurodegenerative disorder with an insidious
onset, which typically appears in older individuals, but may affect people as early as in the
third decade of life (Hardy and Selkoe, 2002). Early onset AD, with symptoms appearing before
65 years of age, represents about 1–2% of all cases. In these patients, the disease commonly
aggregates within families, and about 10% of them show an autosomal dominant pattern of
inheritance. These cases are linked to mutations in the amyloid precursor protein gene (APP,
OMIM 104760), in the presenilin 1 gene (PSEN1, OMIM 104311) and in the presenilin 2 gene
(PSEN2, OMIM 600759) (Tanzi and Bertram, 2001; Pastor and Goate, 2004).
A general problem in clinical genetics, is that when a locus for a disease is found by positional
cloning, and subsequent point mutations are discovered, the gene is sequenced in others with
the disease and novel DNA changes are described whose pathogenicity is then not assessed by
either linkage or association (Hardy and Singleton, 2007). Usually, these mutations are simply
screened for in a number of controls and pathogenicity is assumed if they are not found. In
addition, most sequencing is done in highly studied populations, such as Caucasians or East
Asians and little is done in other populations. The result of this strategy is that variants are
reported and assumed to be pathogenic. This is damaging both from a basic scientific
perspective, because it misleads research on basic mechanisms and from a clinical genetic
perspective, because it could lead to incorrect information being given, especially to those from
under studied communities. Examples of the precedent of misassignment of pathogenicity are
the mutations E318G and InsR352 within PSEN1. Both variants were initially reported to be
pathogenic and were later found to either be normal coding variants (E318G) or a rare non-
pathogenic mutation (InsR352) (Mattila et al., 1998; Boeve et al., 2006). With this background,
we have embarked on a systematic reassessment of pathogenicity of the genes involved in AD.
First, we sequenced the presenilins and APP genes in a large series of early onset AD patients
from Iberia. Then, in order to have a better knowledge of genetic variation within these genes,
we have performed the same sequencing analysis in a series of unrelated African individuals
from seven different populations obtained from CEPH-HGDP, as well as in Iberian controls.
We chose to study this African series because genetic diversity is greatest in Africans and this
population has been little studied. Therefore our chance of finding variants was highest in this
population.
MATERIAL AND METHODS
Alzheimer series
A total of 231 unrelated patients (61.4% women) were recruited from 9 Iberian centers. All
individuals included in this study were Caucasian with apparent Spanish or Portuguese
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ancestry. Mean age at onset was 52.9 years, ranging from 31 to 64. Seventy-four patients (32%)
showed a family history of dementia (defined as at least one affected first degree relative) and
99 (43%) did not report any familial aggregation of disease. In 25% of individuals, no
information was available. For all patients, the diagnosis of probable AD was established
according to the standard Diagnostic and Statistical Manual, revision 4 (DSM IV) (American
Psychiatric Association, 1994) criteria and the National Institute of Neurological Disorders
and Stroke, and the Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) protocol guidelines (McKhann et al., 1984). Written informed consent was obtained
from all participants or surrogates.
Control series
Written informed consent was obtained from 121 neurologically normal and age-matched
control subjects from the Iberian peninsular (mean age at collection 67.4). These were either
patient’s spouses or unrelated caregivers. Coding exons 3 to 12 of PSEN1 and PSEN2, and
exons 16 and 17 of the APP gene were sequenced in this series and in 130 African samples
obtained from the CEPH-HGDP (Cann et al., 2002). These samples originated from 7 different
African populations: 29 Biaka Pygmy, 13 Mbuti Pygmy, 23 Mandenka, 22 Yoruba, 2 San, 17
Bantu, and 24 Mozabite.
DNA Sequencing
Genomic DNA was isolated by standard procedures. The exonic regions of APP (exons 16 and
17), PSEN1 (exons 3–12) and PSEN2 (exons 3–12) genes, as well as the flanking intronic
sequences, were PCR amplified using the respective primers (Goate et al., 1991; Cruts et al.,
1998) and Roche FastStart PCR Master Mix polymerase (Roche Diagnostics Corp., IN). Each
PCR product was sequenced using the same forward and reverse primers with Applied
Biosystems BigDye terminator v3.1 sequencing chemistry and run on an ABI3730xl (Applied
Biosystems) genetic analyzer as per manufacturer’s instructions. The sequences were analyzed
with Sequencher software, version 4.2 (Genecodes, VA).
RESULTS
Mutation screening in AD patients
A total of five novel non synonymous mutations were found. Three of them (H214D, c.
640C>G; L248R, c.743T>G; and S365A, c.1093T>G) were present in PSEN1, one (M174V,
c.520A>G) in PSEN2, and a change in residue 716 of the APP gene (I716F, c.2146A>T). Four
previously described mutations were also detected in PSEN1: T116N, c.347C>T; M233T, c.
697A>C; V272A, c.815T>C; and A260V, c.779C>T.
Additionally, another new mutation in PSEN2 (R71W, c.211T>C) was detected in a 77 year-
old woman with disease onset at 75 years. This patient was not included in the early onset
Alzheimer’s disease series, but was studied at a clinician request.
Screening in Iberian controls
In the 121 controls screened for mutations in PSEN1, PSEN2 and APP we found no non-
synonymous changes.
Screening in African individuals
Two non-synonymous changes were found in the PSEN1 gene in the African series: the
previously reported mutation R35Q (c.104G>A) (Rogaeva et al., 2001; Raux et al., 2005) which
was present in one Mozabite individual and a new variant (V191A, c.572T>C), found in a San
subject.
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In the PSEN2 gene we found three new non-synonymous changes (R29H, c.86C>T; L143H,
c.428T>A; and A252T, c.754G>A). Strikingly, twenty individuals presented the R62H (c.
185G>A) variation, which had been previously described as a variant with an unclear
pathogenic role in AD (Cruts et al., 1998).
In the APP gene, a new non-synonymous variation (H733P, c.2198A>C) was found in an
individual from the Mandenka population.
DISCUSSION
Mutations found in Alzheimer cases and their interpretation
APPI716F: exon 17; transmembrane (TM) domain of the protein. APOE 3/3—The
novel APP I716F is associated with the earliest age at onset described for this locus. Clinical
symptoms of the proband started at the age of 31, and the patient died two years later.
Neuropathological examination revealed the presence of neurofibrillary degeneration (stage
VI of Braak and Braak) (Braak and Braak, 1991) and amyloid deposits (stage C), thus
confirming the clinical diagnosis. The patient’s father died at age 41 with clinically diagnosed
Alzheimer’s disease. Although we were not able to demonstrate segregation of the mutation
with the disease in this family, it is likely to be a pathogenic variant, since other mutations have
been described in the same residue (I716V and I716T) (Eckman et al., 1997; De Jonghe et al.,
2001; Terreni L et al., 2002).
PSEN1 T116N: Exon 5, hydrophilic loop I (HL-I), conserved domain in PSEN2
T122, where pathogenic variants (T122P and T122R) have been described.
APOE 3/4—This mutation was found in a man with onset of symptoms at age 37. It has
previously been reported as a pathogenic mutation on three occasions (Romero et al., 1999;
Rogaeva et al., 2001; Raux et al., 2005), with some segregation information and with an onset
age between 30 and 40 years, being associated with an aggressive familial type of AD with a
rapid progression. In the same residue, the T116I mutation was also reported (La Bella et al.,
2004; Raux, Guyant-Marechal, Martin, Bou, Penet, Brice, Hannequin, Frebourg and Campion,
2005). According to the algorithm we propose (Figure 2) this is a Definitely Pathogenic
mutation.
PSEN1 H214D: Exon 7, HL-IV, conserved in H220 PSEN2 domain where no
mutations are described. APOE 3/3—This mutation has not been previously reported. It
was found in a woman with first clinical symptoms at the age of 55, including atypical signs
such as bradykinesia and mild bilateral action tremor. Family history was positive: the father
and grandmother of the proband presented late onset dementia. This mutation alters a conserved
residue between the two presenilins where the H214Y mutation was previously described in
one family (Raux et al., 2005). According to our algorithm (Figure 2), this mutation is
considered to be Possibly Pathogenic.
PSEN1 M233T: Exon 7, TM-V, residue conserved in PSEN2 M239, where M239V
and M239I are described. APOE 3/3—This mutation was found in a man who presented
the first clinical symptoms at age 35 and died at the age of 42. The proband was first observed
in a psychiatric hospital presenting atypical first symptoms with frontal profile (dysexecutive
syndrome) and behavioural symptoms (depression/apathy and aggressiveness). He also
presented extrapyramidal signs such as dysarthria, left hand apraxia, face and foot dystonia
and pyramidal signs (Babinski). Other late signs included myoclonus and tonic-clonic seizures.
Neuroimaging studies revealed hippocampal and bi-parietotemporal atrophy.
The family history was unclear. This mutation has been reported several times before (Kwok
et al., 1997; Campion et al., 1999; Raux et al., 2005), as other mutations in the same residue
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(M233L, M233V and M233I) (Aldudo et al., 1999; Houlden et al., 2001; Rogaeva et al.,
2001; Mendez and McMurtray, 2006). It alters a conserved residue between PSEN1 and
PSEN2 located in the fifth transmembrane domain. Pathogenic mutations have also been
reported in the homologous PSEN2 residue. It produces a greater proportion of Aβ42 (Scheuner
et al., 1996; Qi et al., 2003; Qi-Takahara et al., 2005) and fits the helix rule (Hardy and Crook,
2001), aligning with other mutations in transmembrane domain 5 (Figure 1). This mutation is
Definitely Pathogenic (Figure 2).
PSEN1 L248R: Exon 7, TM-VI, residue not conserved in PSEN2 V254, no
mutations described. APOE 3/3—This mutation has not been reported before. It was
found in a man presenting an age at onset of 54 years that died at the age of 65. Neuroimaging
studies revealed a prominent atrophy in the lateral fissure together with a less prominent atrophy
in parietofrontal regions. Family history was reported as negative. The mutation L248R does
not alter a conserved residue between presenilins (V254 in PSEN2) and is located in the sixth
transmembrane domain of PSEN1. Although it aligns with other mutations found in the same
transmembrane domain (Figure 1), the paucity of the genetic data means that we cannot be
certain of the pathogenicity of this mutation. We would assign this mutation as Possibly
Pathogenic (Figure 2).
PSEN1 A260V: Exon 8, TM-VI, residue conserved in PSEN2 A266 where no
mutations are described. APOE 3/3—This mutation was found in a woman who
presented the first clinical symptoms at the age of 30. Imaging studies revealed hippocampal
and parietotemporal atrophy. SPECT revealed bilateral temporoparietal hypoperfusion. Family
history was positive: the mother, one aunt and one cousin developed early onset dementia (<40
years). This mutation has been reported several times before (Rogaev et al., 1995; Ikeda et al.,
1996). It alters a conserved residue between presenilins (PSEN2 A266) and is located in the
sixth transmembrane domain of PSEN1. It aligns with other mutations in this domain (Figure
1) and increases the Aβ 42/Aβ 40 ratio (Kametani et al., 2001). This mutation is Definitely
Pathogenic (Figure 2).
PSEN1 V272A: Exon 8, HL-VIa, residue conserved in PSEN2 V278 where no
mutations are described. APOE 3/3—This mutation was found in a man who at the age
of 34 years presented myoclonus and dementia. The patient died at age 42 and had a positive
familial history of dementia: the father and three siblings also presented with dementia. These
three siblings also carried the V272A mutation. This mutation alters a residue conserved
between PSEN1 and PSEN2 but is not in a transmembrane domain (HL-VIa). It was previously
reported in a three generations family with four affected subjects, two of which carried the
V272A mutation, and associated with an increased Aβ42 levels in plasma (Jimenez-Escrig et
al., 2004). Interpretation of these data as in the scheme presented in Figure 2 indicates that this
mutation is Definitely Pathogenic.
PSEN1 S365A: Exon 10, HL-VIb, residue not conserved in PSEN2 it does not
align with any aminoacid in PSEN2. APOE 4/4—The PSEN1 S365A mutation is a novel
variation. It was found in a woman with clinical symptoms beginning at age 55, and was not
present in her two healthy siblings. Although the proband’s father suffered from dementia, in
him, the disease started at the age of 70. Biological specimens were not available and no further
segregation studies were possible. A mutation at this residue (S365Y) has been previously
reported in a patient, who also carried the PSEN1 M146V mutation, which is almost certainly
pathogenic (Rogaeva et al., 2001). This residue is not conserved between PSEN1 and
PSEN2 and is not in a transmembrane domain (HL-VIb). Clearly, we cannot be certain whether
this variant is pathogenic. We suggest this mutation is Possibly Pathogenic (Figure 2).
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PSEN2 R71W: Exon 4, N-Terminal, residue not conserved in PSEN1 Q65. APOE
2/4—This novel variant was found in an elderly sporadic Alzheimer case which was not part
of the central screening in this paper. Neuroimaging features included chronic periventricular
microangiopathic leukoencephalopathy with multiple nucleo-capsular and periventricular
white matter lacunar infarctions. This mutation is Possibly Pathogenic.
PSEN2 M174V: Exon 6, TM-III, residue not conserved in PSEN1 I168. APOE 3/3
—This novel variant was harbored by a woman who developed Alzheimer’s disease at 54 years
of age. Neuroimaging features included atrophy in both parietal regions (R>L) and SPECT
revealed hypoperfusion in temporoparietal regions (R>L). This variant alters a non conserved
residue between presenilins (I168 in PSEN1) located in the third transmembrane domain of
PSEN2. Due to the lack of family history and the fact that this is a not-conserved residue
between PSEN1 and PSEN2 we assign this mutation as Possibly Pathogenic.
Variations found in African population
APP H733P: found in a Mandenka sample (Exon 17, C-Terminal)—This variant was
found in exon 17 of the APP gene. It alters a residue located in the C-terminal of the protein.
No variants have been reported at this residue or close to this residue before.
PSEN1 R35Q: found in a Mozabite sample (Exon 4, N-Terminal), residue not
conserved in PSEN2 G37—This variant has been described before in 2 families with AD,
but in neither case did it segregate with disease and it was interpreted as non-pathogenic
(Rogaeva et al., 2005). The data we present here suggests this interpretation is correct. The
residue is not conserved in PSEN2 and no studies of the effect of this mutation on Aβ
metabolism have been reported.
PSEN1 V191A: found in a San sample (Exon 7, HL-III, residue conserved in
PSEN2 V197)—This variant has not been reported before. It was found in exon 7 of
PSEN1 and the residue where this mutation occurs is conserved between PSEN1 and PSEN2.
PSEN2 R29H: found in a Mandenka Sample (Exon 3, N-Terminal), residue
conserved in PSEN1 R27—This variation has not been previously reported. It is located
in exon 3 of the PSEN2 gene and alters a residue that is conserved between PSEN1 and PSEN2.
PSEN2 R62H found in 20 African samples (allele frequency 9%) (Exon 4, N-
Terminal), residue conserved in PSEN1 R60—This variant had previously been
reported in a sporadic Alzheimer case. These data indicate it is a relatively common
polymorphism in African populations. This residue, located in the N-terminal of the protein,
is conserved between PSEN1 and PSEN2 (R60 in PSEN1) and studies of the effect of the
variant on Aβ metabolism showed no alteration in the production of Aβ42 (Walker et al.,
2005).
PSEN2 L143H found in a Bantu sample (Exon 5, TM-II, residue not conserved in
PSEN1 A137)—This variant occurs in exon 5 of PSEN2. It alters a residue that is not
conserved between PSEN1 and PSEN2 (A137 in PSEN1), located in the second
transmembrane domain of the protein. No mutations have been reported in the correspondent
residue of PSEN1 and it does not fit with the helix rule for pathogenic mutations.
PSEN2 A252T: found in a Mandenka and in a Yoruba sample (Exon 7, TM-VI,
residue conserved in PSEN1 A246)—This variant, found in exon 7 of the PSEN2 gene
modifies a residue conserved between PSEN1 and PSEN2 (A246 of PSEN1) that localizes in
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the sixth transmembrane domain of PSEN2. Two different pathogenic mutations have been
reported in the corresponding PSEN1 residue.
With this background, we herein propose a scale for grading mutations as not pathogenic,
possibly pathogenic, probably pathogenic and definitely pathogenic (Figure 2). We recognize
that this scale is merely pragmatic and subject to improvement, not least because it is possible
that some variants may increase the risk of disease rather than being truly pathogenic.
1. Segregation: Has the mutation been shown to segregate with the disease? This is
clearly the strongest evidence. We would suggest that if a mutation has been shown
to segregate with the disease in three or more cases in a family it should be regarded
as Definitely Pathogenic and if it has shown segregation in two cases, Probably
Pathogenic.
2. Association: Has the mutation been found in one case and not in controls? Evidence
of association with the disease is fundamentally weaker than segregation because it
is not clear how many controls from different populations have been sequenced. Thus,
one does not know, for any individual mutation, what the denominator is. However,
we suggest that if a mutation has been found in at least three early onset non related
Alzheimer cases and in no controls; and more than 100 controls have been sequenced,
that it be regarded as Probably Pathogenic. If less than three have been found, then
we would suggest the designation as Possibly Pathogenic.
3. Residue and Aβ levels: Have other pathogenic mutations been described in that
residue before? If it is a presenilin mutation, does the mutation alter a residue
conserved between PSEN1 and PSEN2 and, if the residue is in a transmembrane
domain does it follow the helix rule? Does the mutation alter APP processing such
that a greater proportion of Aβ42/Aβ40 ratio is produced? We would suggest that if
two of the answers to any of these questions is “yes”, then this should allow the
“promotion” of a mutation.
4. Obviously, finding the mutation in controls is strong evidence that it is not simply
pathogenic (although small changes in risk will remain a possibility).
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Figure 1.
Example of the alignment of the mutations found in this study (in yellow) and the mutations
previously described (red) in transmembrane domains 5 and 6.
Guerreiro et al. Page 10
Neurobiol Aging. Author manuscript; available in PMC 2010 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Algorithm to classify mutations as possibly pathogenic, probably pathogenic, and definitely
pathogenic.
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